DCTH

Delcath Systems Inc

NASDAQ

Add Alert

497

DCTH

Delcath Systems Inc

NASDAQ

Add Alert

497

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

Filterthenoise

06/16/24 12:06 PM

Post #50,157

Re: #50,156: @Monksdream - DCTH under $10

Straight 🔥 $DCTH

Bullish

Monksdream

06/16/24 10:53 AM

Post #50,156

Re: #50,155: @Filterthenoise - $DCTH strong

DCTH under $10

Filterthenoise

05/11/24 12:13 PM

Post #50,155

$DCTH strong

Bullish

Monksdream

03/24/24 4:10 PM

Post #50,154

DCTH 10Q due 3/26

Filterthenoise

01/31/24 1:38 PM

Post #50,153

$DCTH

Bullish

Filterthenoise

12/01/23 7:17 PM

Post #50,152

Lets go $DCTH

Bullish

green maschine

08/16/23 9:56 AM

Post #50,151

Re: #50,150: @TheFinalCD - 5.80 HI :0)

6 now. That was quick.

Bullish

TheFinalCD

08/16/23 9:20 AM

Post #50,150

Re: #50,147: @dande1990 - HC Wainwright & Co. Maintains Delcath Systems (DCTH)

5.80 HI :0)

green maschine

08/16/23 7:29 AM

Post #50,149

Re: #50,148: @dande1990 - H.C. Wainwright Reaffirms Their Buy Rating on Delcath

The 5 analysts offering 12-month price forecasts for Delcath Systems Inc have a median target of 18.00, with a high estimate of 22.00 and a low estimate of 13.00. The median estimate represents a +216.62% increase from the last price of 5.69.

Bullish

dande1990

08/16/23 6:59 AM

Post #50,148

Re: #50,147: @dande1990 - HC Wainwright & Co. Maintains Delcath Systems (DCTH)

H.C. Wainwright Reaffirms Their Buy Rating on Delcath Systems (DCTH)

TipRanks

Aug. 15, 2023, 09:35 AM

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Delcath Systems (DCTH – Research Report), with a price target of $18.00. The company’s shares opened today at $5.84.

dande1990

08/16/23 6:55 AM

Post #50,147

Re: #50,146: @TheFinalCD - 5.13 LO :/

HC Wainwright & Co. Maintains Delcath Systems (DCTH) Buy Recommendation

Story by George Maybach • 14h

?

Fintel reports that on August 15, 2023, HC Wainwright & Co. maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation.
Analyst Price Forecast Suggests 436.15% Upside
As of August 2, 2023, the average one-year price target for Delcath Systems is 16.73. The forecasts range from a low of 10.10 to a high of $23.10. The average price target represents an increase of 436.15% from its latest reported closing price of 3.12.

TheFinalCD

08/16/23 4:25 AM

Post #50,146

5.13 LO :/

SO FAR

green maschine

08/15/23 3:18 PM

Post #50,145

Re: #50,144: @dande1990 - No... On my app and my laptop I

Hope you get that back working soon. I use TD Ameritrade and so far haven't had any problems with their system.

dande1990

08/15/23 3:13 PM

Post #50,144

Re: #50,143: @green maschine - Wow, bummer. Did they say why?

No... On my app and my laptop I have a message saying they are unable to at the moment

$DCTH

green maschine

08/15/23 3:11 PM

Post #50,143

Re: #50,142: @dande1990 - Fidelity is down. Cant make trades at all. $DCTH

Wow, bummer. Did they say why?

dande1990

08/15/23 3:00 PM

Post #50,142

Re: #50,141: @green maschine - Awesome! I need to get my correct my

Fidelity is down. Cant make trades at all.

$DCTH

green maschine

08/15/23 2:55 PM

Post #50,141

Re: #50,140: @dande1990 - Ive been able to do 5.01 to 5.77

Awesome! I need to get my correct my sleeping habits - kicking myself today.

dande1990

08/15/23 2:53 PM

Post #50,140

Re: #50,138: @green maschine - I'm in at 5.43, went back to bed

Ive been able to do 5.01 to 5.77 and 5.55 to 7.25. In again at 6.33.

green maschine

08/15/23 2:51 PM

Post #50,139

Re: #50,135: @TheFinalCD - $7!!!!!!!!!!!!!! SOLD SOME 6.95 AFTER 7 COULDNT BREAK HARD

Nice move CD. Still climbing. $$DCTH$$

Bullish

green maschine

08/15/23 2:47 PM

Post #50,138

Re: #50,131: @TheFinalCD - 6.50 WAS A NICE POP OFF MY 5.55 ENTRY

I'm in at 5.43, went back to bed and missed the flip today. Oh well might see 10 by EOW.

dande1990

08/15/23 2:36 PM

Post #50,137

Re: #50,136: @TheFinalCD - round ii

This board needs some life!! Lets go $DCTH

TheFinalCD

08/15/23 11:55 AM

Post #50,136

Re: #50,133: @SriMaharaj - Told you guys. Get in now before it's

round ii

filled as low as 6.46 on that DIP

$DCTH

TheFinalCD

08/15/23 11:30 AM

Post #50,135

Re: #50,134: @TheFinalCD - 6.70 LG!!!!!!

$7!!!!!!!!!!!!!!

SOLD SOME 6.95 AFTER 7 COULDNT BREAK HARD

TheFinalCD

08/15/23 11:19 AM

Post #50,134

Re: #50,132: @SriMaharaj - Wait until it cross $6. You will see

6.70 LG!!!!!!

Bullish

SriMaharaj

08/15/23 10:57 AM

Post #50,133

Re: #50,132: @SriMaharaj - Wait until it cross $6. You will see

Told you guys. Get in now before it's too late.

SriMaharaj

08/15/23 10:49 AM

Post #50,132

Re: #50,131: @TheFinalCD - 6.50 WAS A NICE POP OFF MY 5.55 ENTRY

Wait until it cross $6. You will see $10 today or tomorrow.

TheFinalCD

08/15/23 10:10 AM

Post #50,131

Re: #50,130: @green maschine - Yeah there's resistance at that level, but I

6.50 WAS A NICE POP OFF MY 5.55 ENTRY

green maschine

08/15/23 10:06 AM

Post #50,130

Re: #50,128: @TheFinalCD - 6.24 SO FAR BUT THEY QUICKLY SOLD IT

Yeah there's resistance at that level, but I believe it'll break through today. Too much buying pressure here. FDA approval is huge news.

Bullish

Filterthenoise

08/15/23 10:03 AM

Post #50,129

BOOM $DCTH

Bullish

TheFinalCD

08/15/23 9:59 AM

Post #50,128

Re: #50,126: @green maschine - Good morning. I wonder how high this flies today.

6.24 SO FAR BUT THEY QUICKLY SOLD IT OFF TO 5.34

DCTH

Monksdream

08/15/23 8:57 AM

Post #50,127

Early Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

green maschine

08/15/23 8:42 AM

Post #50,126

Re: #50,125: @TheFinalCD - https://finviz.com/quote.ashx?t=DCTH&p=d

Good morning. I wonder how high this flies today.

TheFinalCD

08/15/23 8:37 AM

Post #50,125

Re: #50,122: @harvest1 - Wow stock is down 2 weeks before PDUFA

https://finviz.com/quote.ashx?t=DCTH&p=d

$DCTH 🚨 Approved

Finally after years of try.

Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma. pic.twitter.com/ZCBQZXbgzE
— Ripster (@ripster47) August 15, 2023

green maschine

08/15/23 7:58 AM

Post #50,124

Re: #50,123: @Carlito78 - What ever happened to SamnotSamuel?

Where is everybody?

Carlito78

08/15/23 5:03 AM

Post #50,123

What ever happened to SamnotSamuel?

harvest1

08/02/23 5:36 PM

Post #50,122

Wow stock is down 2 weeks before PDUFA date. Hard to imagine this wont be approved this time with no adcom. Not sure why there arent more buyers. Hopefully there is a pop on approval and they have a quick launch and revenue ramp.

Filterthenoise

03/27/23 10:44 AM

Post #50,121

Re: #50,120: @Jmma - Finally looks promising for real. Had shares few

Finally! Go $DCTH

Bullish

Jmma

03/27/23 9:58 AM

Post #50,120

Finally looks promising for real. Had shares few years ago and got chewed up and spit out . Reverse splits wiped out a lot of investors. Looks like they turned the corner and could become the investment everyone hoped for awhile back. Good luck to those holding.

Filterthenoise

02/09/23 6:47 PM

Post #50,119

No one loving the start of the run?

Bullish

Filterthenoise

01/07/23 1:52 PM

Post #50,118

Re: #50,117: @Filterthenoise - $DCTH... LFG!

Next leg time LFG $DCTH!!

Bullish

Filterthenoise

12/08/22 4:03 PM

Post #50,117

$DCTH... LFG!

Bullish

Filterthenoise

11/11/22 7:14 PM

Post #50,112

Let's GO!

$DCTH

Filterthenoise

11/07/22 10:26 PM

Post #50,111

Another run at it coming

GLTA

harvest1

11/01/22 5:02 PM

Post #50,110

A new corporate presentation was posted to the company's website with alot of updated information.
https://delcath.com/investors/events-presentations/

This company has been left for dead by the market but I think the stock could recover strongly next year after approval if revenues begin to roll in. I would be interested to hear others thoughts on catalysts and stock price targets. I think at least a $100 million market cap should be expected on approval. Longer term at least $250 million market cap when revenues are material. Starting 3 new trials in 2023 will be positive as well. There appears to be little interest or attention for the company now but hopefully that changes after approval. My biggest fear is that they will have to dilute more at these awful rock bottom prices.

Filterthenoise

07/21/22 10:18 PM

Post #50,109

Re: #50,108: @nealhugh - just waiting....................................................................

Here we go...

nealhugh

05/02/22 4:17 AM

Post #50,108

Re: #50,107: @nealhugh - yup--- good chat with GA... TY. Neal

just waiting.........................................................................

nealhugh

03/30/22 4:43 AM

Post #50,107

Re: #50,102: @highstreettrader - Better call Toronto!! Lol

yup--- good chat with GA... TY. Neal

nealhugh

03/10/22 10:40 AM

Post #50,106

Re: #50,098: @highstreettrader - Bought a bunch today. Got way too cheap.

FDA submission Summer/Fall 2022
FDA approval possible within 6 mos of submission

Fund raise? when?

Stock price lousy so wait for the fund raise?

All results on trials and use are good!

TY, Neal

nealhugh

03/07/22 8:39 PM

Post #50,105

Re: #50,103: @nealhugh - Yeah--- I had Covid so I have been

https://ih.advfn.com/p.php?pid=nmona&article=87441339

nealhugh

03/07/22 8:38 PM

Post #50,104

Re: #50,102: @highstreettrader - Better call Toronto!! Lol

Yeah--- I had Covid so I have been delayed!!! :)

Older

Delcath Systems Inc (DCTH)

Followers	497	Posters	1647
Posts (Today)	0	Posts (Total)	50157
Created	05/11/05	Type	Free
Moderators

About Delcath Systems (OTCQB:DCTH)
Delcath Systems was formed in 1988 as a Pharmaceutical and Medical Device company focused on Interventional Oncology. The company is registered in Delaware with offices in New York, New York and Manufacturing , Distribution, Research and Development facilities located in Quensbury, New York. The company currently has 10 patents in their U.S. Intellectual Property portfolio according to the U.S. Patent Office.

Delcath Systems subsidiaries include Delcath Holdings Limited (Ireland), Delcath Systems Limited (Ireland), Delcath Systems B.V. (Netherlands), Delcath Systems Gmbh (Germany) and Delcath Systems UK (United Kingdom).

About CHEMOSAT® and Melphalan/HDS
The Delcath system administers concentrated regional chemotherapy directly to the liver. This “whole organ” therapy is performed by 1) isolating the circulatory system of the liver, 2) infusing the liver with a chemotherapeutic agent, and then 3) filtering the blood prior to returning it to the patient’s circulatory system.

During the procedure, known as percutaneous hepatic perfusion, PHP ®, or PHP therapy, three catheters are placed percutaneously through standard interventional radiology techniques. The catheters temporarily isolate the liver from the body’s circulatory system, allow administration of the chemotherapeutic agent melphalan hydrochloride directly to the liver, and collect blood exiting the liver for filtration by our proprietary filters. The filters absorb the chemotherapeutic agent in the blood, thereby reducing systemic exposure to the drug and related toxic side effects, before the filtered blood is returned to the patient’s circulatory system.

PHP therapy is performed in an interventional radiology suite in approximately two to three hours. Patients remain in an intensive care or step-down unit overnight for observation following the procedure. Treatment with CHEMOSAT® and Melphalan/HDS is repeatable, and a new disposable system is used for each treatment. Patients treated in clinical settings are permitted up to six treatments. In commercial treatment settings, patients have received up to eight treatments. In the United States, melphalan hydrochloride for injection will be included as part of the system, if approved. In Europe, the system is sold separately and used in conjunction with melphalan hydrochloride commercially available from a third party. In our clinical trials, melphalan hydrochloride for injection is provided to both European and United States clinical trial sites.

In the United States, the Melphalan/HDS system is considered a combination drug and device product and is regulated as a drug by the United States Food and Drug Administration (FDA). The Melphalan/HDS system has not been approved for sale in the United States.

In Europe, their proprietary system to deliver and and filter melphalan hydrochloride is marketed under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan. In April 2012, they obtained authorization to affix a CE Mark for the Generation 2 CHEMOSAT® system. The right to affix the CE mark allows the company to market and sell the CHEMOSAT® system in Europe.

In December 2018, Delcath entered into a License Agreement with medac GmbH for the commercialization of the CHEMOSAT® system in Europe. Under the terms of the medac License, medac has the exclusive right to sell and market CHEMOSAT® in all member states of the EU, Norway, Liechtenstein, Switzerland, and the United Kingdom.

Since launching CHEMOSAT® in Europe, over 750 commercial treatments have been performed at over 25 European cancer centers. Physicians in Europe have used CHEMOSAT® to treat patients with a variety of cancers in the liver, primarily ocular melanoma liver metastases, and other tumor types including cutaneous melanoma, hepatocellular carcinoma, cholangiocarcinoma, and liver metastases from colorectal cancer, breast, pancreatic and neuroendocrine.

Declcath Systems currently has two clinical trials underway. The first is the FOCUS Trial and the second is the ALIGN Trial.

The FOCUS Trial is designed to evaluate patients who have melanoma that has spread from the eye to the liver. All patients in the study will be treated with Melphalan/HDS for up to 6 treatments. This study will evaluate the safety and effects of the treatment on how long patients live and how long it takes for the cancer to advance or respond to the treatment.

Study Type: Interventional (Clinical Trial)
Enrollment: 80 participants
Intervention Model: Single Group Assignment
Study Start Date: February 1, 2016

Enrollment in the FOCUS Trial was completed in January 2020. Top line data for the study is expected mid-2020 and an NDA (New Drug Application) filing is expected in Q1 2021.
For more info click here

The ALIGN Trial will evaluate two groups of patients who have intrahepatic cholangiocarcinoma. Each group will receive induction treatment with Cisplatin and Gemcitabine per SOC for 4 treatment cycles. Following induction treatment patients will be randomize (1:1), to 2 arms of treatment. One group (50%) will receive high dose chemotherapy delivered specifically to the liver, while the other group (50%) will continue treatment with Cisplatin and Gemcitabine. Patient in each group will get repeating cycles of treatment until the cancer advances. All patients will be followed until death. This study will compare the overall survival (OS) in patients with intrahepatic cholangiocarcinoma. The ALIGN Trial has an estimated completion date of January 2023.

Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 295 participants
Intervention Model: Parallel Assignment
Study Start Date: April 10, 2018

The Primary Completion date for this study is estimated to be January 2023..
For more info click here

Delcath Systems securities originally came on the market on June 16, 2000 with an IPO offering of 1.2m shares priced at $6.00 per share. Securities were listed on both the NASDAQ and Boston Stock Exchange. The stock moved from the NASDAQ to the OTCQB on September 15, 2017 after the company Voluntarily Delisted it from NASDAQ and requested an Accelerated listing in the OTC marketplace.

Stock Split History

Since their initial public offering in 2000, Delcath have affected five reverse stock splits for a cumulative ratio since their IPO of 1:31,360,000,000. Each such reverse split has resulted in an effective decline in the price of their common stock.

Split #	Date	Ratio
1	April 9, 2014	1:16
2	July 21, 2016	1:16
3	November 6, 2017	1:350
4	May 2, 2018	1:500
5	December 24, 2019	1:700

Delcath Share Structure as of 23 January 2020

Common Shares Authorized:	1,000,000,000
Common Shares Outstanding:	70,056
Preferred Shares Authorized:	10,000,000
Preferred Shares Outstanding:	41,447

Delcath Warrants and Options as of 23 January 2020

Warrants:	29	($42; exp 2/2020 - 10/2021)
2019 Warrants:	1,826,579	($23.04; exp 12/2024)
Options:	1,640
Total Warrants/Options:	1,828,248

Shares Reserved for Conversion as of 23 January 2020

Preferred Stock:	1,799,093
Convertible Notes:	63,493
Total Reserved:	1,862,586

Total shares issued and reserved as of 23 January 2020
3,760,890

Delcath Shareholder Information

Management and BOD (Common Stock)

Jennifer K. Simpson, Ph.D.	: 2,965
John Purpura, M.S.	: 2,830
William D. Rueckert	: 2,619
Roger G. Stoll, Ph.D.	: 4,047
Marco Taglietti, M.D.	: 2,606
Total Shares	: 21,459